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The effects of novokinin, an AT2 agonist, on blood pressure, vascular responses, and
levels of ADMA, NADPH oxidase, and Rho kinase in hypertension induced by NOS
inhibition and salt
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Background/aim: The effects of AT2 receptor agonist novokinin on blood pressure, eNOS, NADPH oxidase, protein arginine
methyltransferases (PRMTs), and Rho kinase in hypertension were investigated. Furthermore, in isolated thoracic aorta rings, contractile
and dilator responses were studied.
Materials and methods: To develop hypertension, L-NAME was administered intraperitoneally and salt was given with tap water
(1%) for 4 weeks. Novokinin was administered intraperitoneally for the last 2 weeks. Blood pressures were measured using the tail-cuff
method and enzyme levels by real-time polymerase chain reaction in aortic tissues.
Results: Blood pressure increased significantly in hypertensive rats. Novokinin reduced the blood pressure in the hypertensive group.
While the contractile responses to increasing doses of angiotensin II were increased, vascular reactivity (Emax) and sensitivity (EC50)
to acetylcholine were decreased in hypertensive rats. In novokinin-treated hypertensive groups, the EC50 value decreased and the Emax
value for acetylcholine significantly increased. The levels of Rho kinase and PRMT expression increased and the level of eNOS expression
decreased in the hypertensive group. In novokinin-treated rats, ADMA, NADPH oxidase, and Rho kinase tended to decreased, but these
changes did not reach statistical significance.
Conclusion: Although further studies are needed to determine its effectiveness, the AT2 agonist novokinin may be a novel agent that is
promising in terms of protective effects for the treatment of hypertension.
Key words: ADMA, AT2 receptor, hypertension, nitric oxide, novokinin, Rho kinase

1. Introduction
Hypertension remains a challenging clinical problem.
Although recent advances have been made in the
treatment of hypertension, the majority of patients treated
with antihypertensive agents not optimally controlled.
Additional pharmacologic treatments could ameliorate
this situation (1). There are many responsible mechanisms
that cause essential hypertension. Endothelial dysfunction
characterized by a reduction in the bioavailability of
nitric oxide (NO) and increased plasma volume induced
by excessive salt intake may play important roles in the
development and persistence of hypertension (2).
The renin–angiotensin–aldosterone system (RAAS)
is an important pharmacologic target because it plays
a substantial role in the development of hypertensionrelated organ damage. Although the RAAS can be
* Correspondence: selcukilhan52@gmail.com

blocked by angiotensin converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs),
these pharmacologic manipulations do not completely
suppress the RAAS and the development of target organ
damage because ACE inhibitors and ARBs cause the
reduction of negative feedback and lead to a compensatory
increase in renin synthesis (3). Therefore, additional novel
methods for RAAS blockade may provide better control of
hypertension and prevention of organ damage.
Angiotensin II (Ang-II) induces vasoconstriction,
aldosterone secretion, sympathetic activation, renal
sodium reabsorption, and cell growth via the activation
of AT1 receptors. Increasing experimental evidence
demonstrates that Ang-II type-2 receptor (AT2-R)
activation elicits vasodilatation, sodium excretion, blood
pressure reduction, and antigrowth, proapoptotic, and

1249

MUTLU et al. / Turk J Med Sci
antiinflammatory effects and thereby counteracts the
effects of AT1 receptors (4,5). It has also been shown
that AT2-R regulates RAAS activity by inhibiting renin
biosynthesis (6). AT2-R activation leads to stimulation of
bradykinin, nitric oxide, and prostaglandin production
(7). Due to this effect, AT2 may enhance renal perfusion.
These findings imply that AT2-R may be a potential novel
therapeutic approach in hypertensive conditions.
The RAAS is associated with many enzymes and
molecules that contribute to the development and
maintenance of hypertension, such as nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase,
Rho kinase, asymmetric dimethylarginine (ADMA),
and endothelial nitric oxide synthase (eNOS). Elevated
plasma concentrations of ADMA, an endogenous nitric
oxide synthase inhibitor, were reported in cardiovascular
diseases, such as hypertension, hypercholesterolemia,
coronary artery disease, and acute coronary syndrome,
as well as diabetes mellitus, all of which are associated
with endothelial dysfunction (8). ADMA is generated by
protein methyltransferase (PRMT) (9). NADPH oxidase
enzymes are the major sources of reactive oxygen species
in the vessel wall. Ang-II activates NADPH oxidase via AT1
receptor and leads to endothelial dysfunction. Rho kinase
induces the enhancement of vascular tone and decreases
the blood flow indirectly through negative effects on
eNOS activity (10). Oxidative stress-related parameters
such as NADPH oxidase, Rho kinase, and ADMA are
important pharmacological targets for the treatment of
cardiovascular diseases.
Novokinin is a new potent antihypertensive peptide
acting through the AT2 receptor. Its effect is not known
on blood pressure in N-[omega]-nitro-L-arginine
methyl ester (L-NAME)- and salt-induced hypertension.
According to our knowledge, the effects of novokinin
on eNOS, NADPH oxidase, ADMA, and Rho kinase in
hypertension are unclear, as are the ways in which it affects
vascular functions (Ang-II and α1-adrenergic-induced
contractions, acetylcholine (ACh)-mediated dilator
responses).
Many studies have revealed that the interaction
between NO and the autonomic nervous system plays
an important role in the regulation of the cardiovascular
system (11). The cholinergic system is active in balancing
arterial hypertension. The cholinergic neurotransmitter
ACh may induce eNOS enzyme.
In this study, to determine the contributions of
NADPH oxidase, Rho kinase, ADMA, PRMT, and
eNOS and to investigate the effect of an AT2-R agonist
(novokinin) on these parameters and systolic blood
pressure in hypertension, Sprague Dawley male rats were
given L-NAME and salt. Additionally, α1-adrenergic
contractions, ACh-induced relaxation, and the roles of
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AT2-R and Rho kinase in Ang-II-induced contractions in
vessels in all groups were studied.
2. Materials and methods
2.1. Chemicals
Phenylephrine (Phe), ACh, L-NAME, novokinin, and
Ang-II were purchased from Sigma Aldrich (St. Louis,
MO, USA). All drugs were dissolved in saline.
2.2. Animals and treatments
Twenty-eight Sprague Dawley male rats, weighing 240–
280 g, were housed in quiet rooms with a 12-h light/
dark cycle (0700–1900 hours) and allowed a commercial
standard rat diet and water ad libitum. The experiments
were performed in accordance with the Guide for the
Care and Use of Laboratory Animals (DHEW Publication
(NIH) 8523, 1985). This study was approved by the relevant
institutional animal ethical committee (211-5-79).
Rats were divided into four groups. There were 7
rats in each group. L-NAME and salt were given to rats
for development of hypertension. L-NAME was injected
intraperitoneally (40 mg/kg per day, once a day) and salt
(1%) was administered with drinking water. Novokinin
(0.1 mg/kg per day) was administered intraperitoneally for
2 weeks. 1) Control group: Saline was administered at 0.5
mL intraperitoneally per day for 4 weeks. 2) Novokinin:
After physiological serum (0.5 mL per day), novokinin
was given during the last 2 weeks intraperitoneally. 3)
Hypertension (HT) group: L-NAME and sodium chloride
were administered for 4 weeks. 4) Hypertension (HT) +
novokinin group: L-NAME and sodium chloride were
administered for 4 weeks, and also novokinin was given in
last 2 weeks intraperitoneally (Figure 1).
2.3. In vivo studies
Systolic blood pressure (SBP) was measured by tail-cuff
method (MAY BPHR 9610-PC, Commat Ltd., Ankara,
Turkey) at the beginning of the protocol and the 14th
and 28th days of experiments, as described previously in
restrained animals (12). Five measurements were taken for
each rat and then the average thereof was calculated.
2.4. In vitro studies
The freshly harvested thoracic aortas of rats decapitated
under urethane anesthesia were cleaned from fat and
connective tissues. Rings, each approximately 0.4 cm
long, were prepared from a segment of thoracic aorta
and mounted on FDT 05 (MAY Force–Displacement
Transducer) MP 36 (BİOPAC) in temperature-controlled
baths (37 °C) of 20 mL containing Krebs Henseleit buffer
(mmol/L: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25, glucose 11; pH 7.4) and oxygenated with
a 95% O2 + 5% CO2 mixture. Vessels were equilibrated for
60 min at 2.0 g resting tension, with changes of bathing
fluid every 15 min.
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Figure 1. Experimental protocol.

The presence of the endothelium was tested by
application of ACh. The dose–response curve of Phe
was determined by the application of increasing doses of
Phe (from 10–9 to 10–4 M) and a submaximal dose of Phe
was obtained. After the contraction of the submaximal
dose of Phe, at the plateau of the contraction response
to Phe, doses of Ach were applied (from 10–9 to 10–5 M)
and the dose-response curve of Ach was obtained. The
50% maximal effective concentration (EC50) and Emax
(maximal contraction for Phe and maximal relaxation for
Ach) values of Phe and ACh were calculated. To investigate
the roles of AT1 and AT2 receptors and the Rho kinase
pathway, Ang-II (10–11 to 10–6 M/L) dose–response curves
were calculated for Phe (10–6) precontracted vessels.
2.5. Real-time polymerase chain reaction
Gene expression was analyzed using real-time polymerase
chain reaction (RT-PCR). Sections of the thoracic aorta
weighting 20 mg were prepared for each sample, and the
tissue was disintegrated by MAGNA laser. A genomic
RNA purification kit was used for isolation of RNA (High
Pure PCR Tissue RNA Kit, Cat. No. 12033674 0019). Using
total RNA isolated from real-time PCR, cDNA synthesis
was performed. Related parameters and mRNA sequences
were amplified by PCR using specific primers. Related to
the amplification kit (eNOS Assay ID 500 228, 502 043
ID Protein Arginine Methyltransferases (PRMT) Assay,
Enzymatic Assay ID 502 973, 500 277 ID Rho Kinase
Assay, Roche), the LightCycler and TaqMan Master Kit
(Roche Cat. No. 04535286001 or 04735536001) were used.
Amplifications (LightCycler, Roche) were performed in
a RT-PCR device (LightCycler, Roche). Messenger RNA

expression was normalized by beta-actin and expressed as
the ratio of target to control value.
2.6. Data analysis
Data were analyzed using SPSS 21.0. One-way ANOVA was
performed and post hoc multiple comparisons were made
using the Tukey HSD test. Results are presented as mean ±
SEM; P < 0.05 was regarded as statistically significant.
3. Results
3.1. Blood pressure
In the HT and HT + novokinin groups, SBP increased at
the 14th day significantly (Table 1). While there was no
significant difference between 14th and 28th day blood
pressure in the HT group, SBP decreased significantly in the
HT + novokinin group at the 28th day (P < 0.05) (Table 1).
There was no significant reduction in the novokinin group
at the 28th day (Table 1).
3.2. Vasoconstrictor responses to phenylephrine
There was no significant difference between groups in
vasoconstrictor responses (data not shown).
3.3. Vasodilator responses to acetylcholine
In the HT group, the ACh EC50 value was significantly higher
than in the control group (P < 0.05; Table 2). The ACh Emax
value was significantly lower in the HT group compared
to the control group (P < 0.05). Novokinin application
alone significantly reduced the EC50 value compared to
the control. The ACh Emax value was significantly higher
in the novokinin group than the control (P < 0.05). In the
HT + novokinin group, Emax values increased significantly
compared to the HT group (P < 0.05) (Table 2).
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Table 1. Systolic arterial blood pressure at baseline and 14th and 28th days in all experimental
groups.
Groups

Baseline

Day 14

Day 28

Control

107.09 ± 2.46

108.54 ± 3.58

109.07 ± 3.70

Novokinin

115.84 ± 5.05

110.43 ± 4.81

111.28 ± 4.16

HT

114.89 ± 2.59

152.07 ± 5.02 ab*

154.16 ± 8.72

ab*

HT + novokinin

116.69 ± 2.01

161.29 ± 7.01 ab*

134.00 ± 3.84

abc#

Results are represented as mean ± SE.
a, vs. control,
b, vs. novokinin
c, vs. HT
*, vs. baseline
#, vs. day 14, P < 0.05.

3.4. Concentration–response curves for Ang-II in Pheprecontracted vessels
In the HT group, the contractile responses to Ang-II at
increasing doses (10–6 and 10–7) were raised significantly
compared with the control group. In the HT + novokinin
group, contractile responses to Ang-II were decreased
significantly compared with the HT and other treatment
groups (Figure 2).
3.5. The expression levels of PRMT, NADPH oxidase,
eNOS, and Rho kinase
In the HT group, while the expressions of PRMT, NADPH
oxidase, and Rho kinase tended to increase, the expression
of eNOS tended to decrease, but not significantly. The
expressions of PRMT, NADPH oxidase, and Rho kinase
in the HT + novokinin group tended to be lower than in
the HT group, but these changes did not reach statistical
significance (Figures 3–6, respectively).

Table 2. Relaxant responses to acetylcholine after phenylephrine
(10–6 M) application at the end of 4 weeks in all groups.
Relaxant responses in thoracic aorta
Groups

Emax (%)

Control

53.17 ± 0.87

Novokinin

80.50 ± 0.89

7.00 ± 8.30a

HT

47.83 ± 0.54ab

6.24 ± 8.15ab

HT + novokinin

52.33 ± 0.98

6.58 ± 8.22abc

EC50 (–log10)
6.74 ± 8.22
a

bc

Results are represented as mean ± SE.
a, vs. control,
b, vs. novokinin
c, vs. HT, P < 0.05.
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4. Discussion
In the present study, it was found that novokinin lowered the
blood pressure, improved ACh dilator responses, reduced
Ang-II-induced contraction in NOS inhibition and saltcoadministered hypertensive rats. In the novokinin treatment
group, the expressions of Rho kinase, PRMT, and NADPH
oxidase tended to be decreased and the expression of eNOS
was increased in hypertensive rats.
Endothelial dysfunction, oxidative stress, increased
sympathetic activation, and salt retention may play primary
roles in hypertension. Salt-loading augments the degree of
hypertension and lowers its starting time (13). It has been
shown that chronic treatment of rats with L-NAME decreases
NO production, causes impairment of endothelial vasodilator
function, and results in a progressive increase of blood
pressure (14). The current study was done by combining
both methods: salt loading and NOS inhibition-induced
hypertension.
The cholinergic neurotransmitter ACh may induce
eNOS enzyme. eNOS is the enzyme most responsible for the
production of vascular NO. Ang-II can increase oxidative
stress, and oxidative stress may cause inactivity of NO and
this result may provoke cardiovascular diseases (15,16). The
negative effect of oxidative stress on NO may disturb the dilator
(17) effect of cholinergic system, and thus the sympathetic
system may become more dominant in the vascular system.
ADMA, an endogenous and competitive NOS inhibitor,
is an important molecule that decreases in endothelial NO
biosynthesis; accordingly, ADMA may change the cholinergic
activity in vessels in the opposite direction (18). Rho kinase
is able to phosphorylate eNOS by inactivating the enzymes
and may impair NO synthesis (19). The negative correlation
between eNOS and Rho kinase may convert the balance
between the cholinergic system and sympathetic system in
blood pressure in the favor of the sympathetic system.
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Figure 2. Cumulative dose–response curves produced by angiotensin II in phenylephrineprecontracted aortic ring preparations obtained from rats given HT and HT + novokinin and
in control rats. a- vs. control. b- vs. HT + novokinin.

In the present study, the systolic blood pressure
increased in the HT and HT + novokinin groups at the
14th day. Blood pressure was numerically higher on
the 28th day. Novokinin significantly reduced the SBP
compared with the hypertension group. Our findings are
similar to previous studies demonstrating that novokinin
significantly reduced SBP after oral administration at a dose
of 0.1 mg/kg in spontaneously hypertensive rats (20,21).
Its hypotensive activity was inhibited by PD123319, an
AT2 antagonist, in hypertensive rats. Novokinin did not
exhibit hypotensive activity in AT2 receptor-deficient
mice (20,21). Yamada et al. (20) showed that novokinin
caused vasodilatation in isolated mesenteric arteries. The
vasodilator activity of novokinin was blunted by PD123319,
indomethacin, and CAY10441 which is a prostaglandin I2
receptor antagonist. Furthermore, it was found that the
vasorelaxing activity of novokinin could be inhibited by
L-NAME (20,21). In this regard, prostaglandin I2 and NO
contribute to the vasorelaxing activity of novokinin.
In our study, Phe-induced contractions were increased
in the hypertension group, but not significantly so

compared with the control. There was no difference
between other groups in Phe contractile responses. In a
study by Kalliovalkama et al. (22), L-NAME administration
for 4 weeks did not change noradrenaline contractile
responses compared with the control. Likewise, results
of the addition of losartan to the L-NAME-administered
group was not different from the control and L-NAMEadministered groups (22). These results are in agreement
with our study.
ACh generated significantly lower vasorelaxing
response in the hypertension group than the control
group in the current study. In a previous study, relaxations
with ACh were significantly impaired in spontaneous
hypertensive rats (SHRs) compared with the wild type
(17). Administration of 10 mg and 100 mg of L-NAME
significantly suppressed ACh-induced relaxation in aortic
rings compared with the control (23). However, there was
no difference between L-NAME-administered (10, 100
mg) groups.
We observed that contractile response to Ang-II
increased at high doses of Ang-II (10–7 and 10–6). Our
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Figure 3. The expression level of PRMT in aortic tissue from all experimental groups.

Figure 4. The expression level of NADPH oxidase in aortic tissue from all experimental groups.

findings suggest that the administration of L-NAME and
salt may enhance the sensitivity to Ang-II. However, this
observation was not shown in the novokinin-treated
HT group. It might be argued that novokinin treatment
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enhanced the antagonism of the AT2 receptor and so
AT1-induced vasoconstriction might have fallen. In
aortic rings from mice with the 2-kidney, 1-clip Goldbatt
hypertension model, the contractile responses to Ang-II
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Figure 5. The expression level of eNOS in aortic tissue from all experimental groups.

Figure 6. The expression level of Rho kinase in aortic tissue from all experimental
groups.

were attenuated compared with sham-operated animals
(24). It was estimated that the attenuation of AT1-mediated
contraction probably depended on the increased number
of AT2 receptors (16).
We explored the expression of Rho kinase, PRMT,
NADPH oxidase, and eNOS in the aortic tissues from all
experimental groups. It has been suggested that there is a

causal link between hypertension and these enzymes. In
the hypertension group, eNOS expression was decreased.
On the other hand, eNOS expression increased in
treatment groups. In a previous study, male Sprague
Dawley rats given L-NAME in drinking water for 8 weeks
had a decrease of eNOS expression in aortic tissue (25). In
L-NAME-treated rats, administration in the last 4 weeks
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of either enalapril or losartan completely restored eNOS
mRNA levels in aortic tissue (25).
In our study, the expression level of NADPH oxidase
increased in the L-NAME- and salt-given group, but
NADPH oxidase expression in the novokinin-treated
group tended to decrease. In a previous study NADPH
oxidase expression in both the telmisartan-treated and the
losartan-treated SHRs was significantly lower than in the
untreated SHRs (26). In another study it was demonstrated
that NADPH oxidase activity in aldosterone-salt-induced
hypertension was increased in aortic tissue (27).
In the present study, the expression of PRMT, an
enzyme responsible for generating ADMA, was increased
in the HT group and decreased in novokinin-treated
groups. Several studies have demonstrated that ACE
inhibitors or ARBs reduced plasma ADMA levels in
patients with HT, diabetes, or cardiovascular diseases
(8). In a previous study, it was suggested that ADMA
activates the local renin-angiotensin system, and AngII augmentation activates NAD(P)H oxidase via the
AT1 receptor; the production of superoxide impairs the
bioavailability of NO. This mechanism may participate
in the development of endothelial dysfunction, which is
associated with elevated ADMA levels (16).
Increased activity of the Rho/Rho kinase pathway
has been proposed to play an important role in the
development and maintenance of hypertension (28). We

have observed that Rho kinase expression increased in
hypertension, but its expression level was decreased in
novokinin-treated groups. In rats treated with L-NAME,
although oral administration of Y27632 lowered blood
pressure, the level of RhoA was markedly increased in
vessels from L-NAME-treated rats (29).
As results of earlier studies, it was indicated that AT2-R
shows beneficial effects for preventing cardiovascular
diseases, including antiinflammatory, antiapoptotic, and
blood pressure-lowering actions (30). Recent preclinical
models showed that AT2 agonists are effective molecules
and so they may play important therapeutic roles in the
treatment of hypertension and enhance the actions of
currently available RAS inhibitors (30).
The results of our study show that novokinin might
positively affect blood pressure, endothelial function, and
oxidative stress-related parameters. The above effects of
the AT2 agonists were shown for the first time in our study.
Although further studies are needed to determine the
effectiveness of novokinin on cardiovascular diseases, it is
argued that novokinin might support or be an alternative
to the current treatments.
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